行情

THOR

THOR

Synthorx
NASDAQ

实时行情|Nasdaq Last Sale

67.80
+0.09
+0.13%
交易中 12:32 12/10 EST
开盘
67.50
昨收
67.71
最高
68.05
最低
67.50
成交量
77.03万
成交额
--
52周最高
68.05
52周最低
11.00
市值
18.59亿
市盈率(TTM)
-35.1532
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

THOR 新闻

  • SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of SYNTHORX, INC. - THOR
  • PR Newswire.36分钟前
  • Company News for Dec 10, 2019
  • Zacks.3小时前
  • Sanofi Unveils Growth Strategy, Ends Diabetes & CV Research
  • Zacks.3小时前
  • Pharma M&As Continue, Merck, Sanofi to Buy Cancer Drug Firms
  • Zacks.4小时前

更多

所属板块

生物技术和医学研究
+0.64%
制药与医学研究
+0.67%

热门股票

名称
价格
涨跌幅

THOR 简况

Synthorx, Inc. is a biopharmaceutical company. The Company is focused on prolonging and improving the lives of people suffering from cancer and autoimmune disorders. Its platform technology expands the genetic code by adding a new deoxyribonucleic acid (DNA) base pair and is designed to create optimized biologics, which is referred as Synthorins. The Company’s lead product candidate, THOR-707, is a variant of IL-2 designed to kill tumor cells by increasing CD8+ T and natural killer (NK), cells without causing vascular leak syndrome (VLS), observed with IL-2 (aldesleukin). Its cytokine Synthorin programs, including IL-2, IL-10 and IL-15 for the treatment of cancer, and another IL-2 Synthorin program for the treatment of autoimmune disorders.
展开

Webull提供Synthorx Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。